Cancer treatment disparities in HIV-infected individuals in the United States

Journal of Clinical Oncology

Volumn 32, Issue 22, 2014, Pages 2344-2350

  Suneja, Gita ^a   Shiels, Meredith S ^b   Angulo, Rory ^c   Copeland, Glenn E ^d   Gonsalves, Lou ^c   Hakenewerth, Anne M ^e   Macomber, Kathryn E ^d   Melville, Sharon K ^e   Engels, Eric A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CDC   (United States)

^d MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^e TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ANUS CANCER; ARTICLE; BLACK PERSON; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CD4 LYMPHOCYTE COUNT; COLON CANCER; COLORECTAL CANCER; DEMOGRAPHY; DRUG USE; FEMALE; GENDER; HEALTH CARE DISPARITY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; UNITED STATES; UTERINE CERVIX CANCER;

AGED; CONNECTICUT; FEMALE; HEALTHCARE DISPARITIES; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MICHIGAN; MIDDLE AGED; NEOPLASMS; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS; TEXAS;

EID: 84905851584     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.8644     Document Type: Article

References (57)

1. Clifford GM, Polesel J, Rickenbach M, et al: Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425-432, 2005 (Pubitemid 40528605)
2. Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753-762, 2011
3. Silverberg MJ, Chao C, Leyden WA, et al: HIV infection and the risk of cancers with and without a known infectious cause. AIDS 23:2337-2345, 2009
4. Frisch M, Biggar RJ, Engels EA, et al: Association of cancer with AIDS-related immunosuppression in adults. JAMA 285:1736-1745, 2001 (Pubitemid 32259908)
5. Goedert JJ, Coté TR, Virgo P, et al: Spectrum of AIDS-associated malignant disorders. Lancet 351:1833-1839, 1998 (Pubitemid 28279706)
6. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al: Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 32:527-533, 2003 (Pubitemid 36423125)
7. Hogg RS, Heath KV, Yip B, et al: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279:450-454, 1998 (Pubitemid 28082255)
8. Nguyen ML, Farrell KJ, Gunthel CJ: Non-AIDS-defining malignancies in patients with HIV in the HAART era. Curr Infect Dis Rep 12:46-55, 2010
9. Shiels MS, Cole SR, Kirk GD, et al: A metaanalysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52:611-622, 2009
10. Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728-736, 2008 (Pubitemid 351717418)
11. Grulich AE, Li Y, McDonald A, et al: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 16:1155-1161, 2002 (Pubitemid 34533854)
12. Simard EP, Engels EA: Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 51:957-962, 2010
13. Louie JK, Hsu LC, Osmond DH, et al: Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 186:1023-1027, 2002
14. Biggar RJ, Engels EA, Ly S, et al: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 39:293-299, 2005 (Pubitemid 40923208)
15. Brock MV, Hooker CM, Engels EA, et al: Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: Implications for patient care. J Acquir Immune Defic Syndr 43:47-55, 2006 (Pubitemid 44306487)
16. Spano JP, Atlan D, Breau JL, et al: AIDS and non-AIDS-related malignancies: A new vexing challenge in HIV-positive patients-Part II, Cervical and anal squamous epithelial lesions, lung cancer, testicular germ cell cancers, and skin cancers. Eur J Intern Med 13:227-232, 2002 (Pubitemid 34627051)
17. Suneja G, Shiels MS, Melville SK, et al: Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 27:459-468, 2013
18. National Cancer Institute: HIV/AIDS Cancer Match Study. http://hivmatch.cancer.gov
19. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, version 2.2013. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#site
20. Young JJ, Roffers S, Ries L, et al: SEER Summary Staging Manual 2000: Codes and Coding Instructions. Bethesda, MD, National Cancer Institute NIH publication 01-4969, 2001
21. Kaplan LD, Lee JY, Ambinder RF, et al: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005 (Pubitemid 41208563)
22. Höcht S, Wiegel T, Kroesen AJ, et al: Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection. Acta Oncol 36:799-802, 1997 (Pubitemid 28088464)
23. Edelman S, Johnstone PA: Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: Outcomes and toxicities. Int J Radiat Oncol Biol Phys 66:206-211, 2006 (Pubitemid 44175642)
24. Cleator S, Fife K, Nelson M, et al: Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 36:754-758, 2000 (Pubitemid 30179747)
25. Wexler A, Berson AM, Goldstone SE, et al: Invasive anal squamous-cell carcinoma in the HIV-positive patient: Outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 51:73-81, 2008
26. Errante D, Tirelli U, Gastaldi R, et al: Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection: A prospective study of 17 patients-The Italian Cooperative Group on AIDS and Tumors (GICAT). Cancer 73:437-444, 1994 (Pubitemid 24030626)
27. Levine AM, Li P, Cheung T, et al: Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: A prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 24:444-450, 2000
28. Weiss R, Mitrou P, Arasteh K, et al: Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-Results of the German Multicenter Trial. Cancer 106:1560-1568, 2006
29. Ratner L, Lee J, Tang S, et al: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171-2178, 2001 (Pubitemid 32366971)
30. Jacobson CA, Abramson JS: HIV-associated Hodgkin's lymphoma: Prognosis and therapy in the era of cART. Adv Hematol 2012:507257, 2012
31. Montoto S, Shaw K, Okosun J, et al: HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 30:4111-4116, 2012
32. Persad GC, Little RF, Grady C: Including persons with HIV infection in cancer clinical trials. J Clin Oncol 26:1027-1032, 2008
33. Alshafie MT, Donaldson B, Oluwole SF: Human immunodeficiency virus and lung cancer. Br J Surg 84:1068-1071, 1997 (Pubitemid 27359475)
34. Bertolaccini L, Lybéris P, Soncini S, et al: Clinical characteristic lung cancer in HIV-infected patients. Therapy 6:903-906, 2008
35. Flores MR, Sridhar KS, Thurer RJ, et al: Lung cancer in patients with human immunodeficiency virus infection. Am J Clin Oncol 18:59-66, 1995
36. Karp J, Profeta G, Marantz PR, et al: Lung cancer in patients with immunodeficiency syndrome. Chest 103:410-413, 1993 (Pubitemid 23070735)
37. Spano JP, Massiani MA, Bentata M, et al: Lung cancer in patients with HIV infection and review of the literature. Med Oncol 21:109-115, 2004 (Pubitemid 39108000)
38. Tirelli U, Spina M, Sandri S, et al: Lung carcinoma in 36 patients with human immunodeficiency virus infection: The Italian Cooperative Group on AIDS and Tumors. Cancer 88:563-569, 2000 (Pubitemid 30056930)
39. Vyzula R, Remick SC: Lung cancer in patients with HIV-infection. Lung Cancer 15:325-339, 1996 (Pubitemid 26399512)
40. Mani D, Haigentz M Jr, Aboulafia DM: Lung cancer in HIV infection. Clin Lung Cancer 13:6-13, 2012
41. Wosnitzer MS, Lowe FC: Management of prostate cancer in HIV-positive patients. Nat Rev Urol 7:348-357, 2010
42. Berretta M, Lleshi A, Cappellani A, et al: Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 8:218-222, 2010
43. Chapman C, Aboulafia DM, Dezube BJ, et al: Human immunodeficiency virus-associated adenocarcinoma of the colon: Clinicopathologic findings and outcome. Clin Colorectal Cancer 8:215-219, 2009
44. Antoniou T, Tseng AL: Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44:111-145, 2005 (Pubitemid 40188937)
45. Rudek MA, Flexner C, Ambinder RF: Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 12:905-912, 2011
46. Deeken JF, Tjen-A-Looi A, Rudek MA, et al: The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 55:1228-1235, 2012
47. Bower M, Collins S, Cottrill C, et al: British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 9:336-388, 2008 (Pubitemid 352015641)
48. Brook MG, Jones K, Bower M, et al: Management of HIV-related lymphoma in HIV treatment centres in North Thames Region. Int J STD AIDS 15:765-766, 2004 (Pubitemid 39540706)
49. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, version 2.2013. http://www.nccn.org
50. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Non-Small-Cell Lung Cancer, version 2.2012. http://www.nccn.org
51. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma, version 2.2013. http://www.nccn.org/
52. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, version 2.2013. http://www.nccn.org
53. Simard EP, Pfeiffer RM, Engels EA: Mortality due to cancer among people with AIDS: A novel approach using registry-linkage data and population attributable risk methods. AIDS 26:1311-1318, 2012
54. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389, 2003 (Pubitemid 46606420)
55. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94:334-357, 2002 (Pubitemid 34257478)
56. Shiels MS, Pfeiffer RM, Engels EA: Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 153:452-460, 2010
57. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Overview. http://www.cdc.gov/hiv/statistics/surveillance/incidence/